Monitoring SARS-CoV-2 seroprevalence over time among pregnant women admitted to delivery units: Suitability for surveillance

Imagem de Miniatura
Arquivos
art_MIYADAHIRA_Monitoring_SARSCoV2_seroprevalence_over_time_among_pregnant_women_.PDF (858.52 KB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
ALEXANDER, Neal
MAYAUD, Philippe
Citação
PLOS ONE, v.18, n.1, article ID e0280109, 15p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
ObjectivesTo determine SARS-CoV-2 seroprevalence over time and risk factors among pregnant women at delivery in Sao Paulo, Brazil; and to evaluate the suitability of pregnant women as a sentinel population for SARS-CoV-2 serosurveillance. MethodsUnselected consecutive pregnant women presenting at the labor ward of a single large hospital between July 20(th) 2020 to February 21(st) 2021 were enrolled and tested for SARS-CoV-2 serology using two assays: the rapid chromatic Wondfo One Step (for total IgA and IgG detection) and Roche Elecsys assay (detecting anti-nucleoprotein [N] IgG). SARS-CoV-2 seroprevalence was computed as smooth spline function over time with 95% confidence intervals (CI). Risk factors were evaluated for positivity by each assay. We compared timepoint seroprevalence by the two assays with four concomitant community household surveys (HHS), in which the Roche assay was used, to determine the sensitivity and relevance of the pregnant women population as sentinel population. ResultsOverall SARS-CoV-2 seroprevalence was 28.9% (221/763) by Roche and 17.9% (137/763) by Wondfo. Reported symptoms experienced during pregnancy were all significantly correlated with being SARS-CoV-2 seropositive at delivery with any assay (with odds-ratios ranging from 3.0 [95% CI: 2.1-4.3] for coryza to 22.8 [95% CI: 12.3-46.6] for ageusia). Seropositivity by either assay was high in women at delivery in the early period of the pandemic (June 2020), compared with seropositivity in women from the concomitant HHS: 44.1% (95% CI: 21.8-66.4) for Roche, 54.1% (30.9-78.5) for Wondfo, versus 11.4% (95% CI: 9.2-13.6) for HHS. For later periods (October 2020 and January 2021), the seropositivity in women at delivery measured by Roche corresponded well with the prevalence found among women in the HHS using the same assay, whilst prevalence measured by Wondfo dropped. ConclusionsWomen at delivery represent a highly exposed and readily accessible population for sentinel surveillance of emerging infections such as SARS-CoV-2.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/53009
Referências
  1. Agresti A, 1998, AM STAT, V52, P119, DOI 10.2307/2685469
  2. Allotey J, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3320
  3. [Anonymous], 2022, PAINEL CORONAVIRUS
  4. [Anonymous], 2020, SOROEPI MSP
  5. [Anonymous], 2020, CORONAVIRUS DIS COVI
  6. [Anonymous], 2020, INTERIM GUIDELINES C
  7. [Anonymous], 2020, WHO CORONAVIRUS COVI
  8. [Anonymous], 2020, DIARIO OFICIAL ESTAD
  9. [Anonymous], 2020, B DIARIO COVID 19
  10. Cavaliere AF, 2022, J MATERN-FETAL NEO M, V35, P3005, DOI 10.1080/14767058.2020.1793317
  11. Chi H, 2021, J MICROBIOL IMMUNOL, V54, P69, DOI 10.1016/j.jmii.2020.07.024
  12. COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104
  13. Cosma S, 2021, J MED VIROL, V93, P537, DOI 10.1002/jmv.26267
  14. Costa SF, 2020, J CLIN VIROL, V131, DOI 10.1016/j.jcv.2020.104592
  15. Crovetto F, 2020, LANCET, V396, P530, DOI 10.1016/S0140-6736(20)31714-1
  16. Dashraath P, 2020, AM J OBSTET GYNECOL, V222, P521, DOI 10.1016/j.ajog.2020.03.021
  17. Di Germanio C, 2021, TRANSFUSION, V61, P2677, DOI 10.1111/trf.16555
  18. Di Toro F, 2021, CLIN MICROBIOL INFEC, V27, P36, DOI 10.1016/j.cmi.2020.10.007
  19. Dinardo CL, 2021, TRANSFUS APHER SCI, V60, DOI 10.1016/j.transci.2021.103102
  20. Diriba K, 2020, EUR J MED RES, V25, DOI 10.1186/s40001-020-00439-w
  21. Ellington S, 2020, MMWR-MORBID MORTAL W, V69, P769, DOI [10.15585/mmwr.mm6925a1, 10.15585/mmwr.mm6925a1externalicon]
  22. Elnasser Z, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000027537
  23. Fassett MJ, 2020, AM J PERINAT, V37, P1110, DOI 10.1055/s-0040-1714060
  24. Flannery DD, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd5709
  25. Gagliardi L, 2020, AM J OBSTET GYNECOL, V223, P291, DOI 10.1016/j.ajog.2020.05.017
  26. Galanis P, 2021, J HOSP INFECT, V108, P120, DOI 10.1016/j.jhin.2020.11.008
  27. Gao YD, 2021, ALLERGY, V76, P428, DOI 10.1111/all.14657
  28. Giuliani F, 2022, AM J OBSTET GYNECOL, V227, DOI 10.1016/j.ajog.2022.04.019
  29. Goldfarb IT, 2020, INFECT CONT HOSP EP, V41, P1095, DOI 10.1017/ice.2020.255
  30. Haizler-Cohen L, 2021, AM J OBSTET GYNECOL, V224, P112, DOI 10.1016/j.ajog.2020.09.022
  31. HASTIE T, 1986, STAT SCI, V1, P297, DOI 10.1214/SS/1177013604
  32. Ilter PB, 2022, ULTRASOUND OBST GYN, V60, P96, DOI 10.1002/uog.24916
  33. Juan J, 2020, ULTRASOUND OBST GYN, V56, P15, DOI 10.1002/uog.22088
  34. Kayi I, 2021, CLIN MICROBIOL INFEC, V27, P1242, DOI 10.1016/j.cmi.2021.05.036
  35. LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
  36. Maeda MDY, 2021, PRENATAL DIAG, V41, P998, DOI 10.1002/pd.5980
  37. McClymont E, 2022, JAMA-J AM MED ASSOC, V327, P1983, DOI 10.1001/jama.2022.5906
  38. Miller TE, 2020, FASEB J, V34, P13877, DOI 10.1096/fj.202001700RR
  39. Prabhu M, 2020, BJOG-INT J OBSTET GY, V127, P1548, DOI 10.1111/1471-0528.16403
  40. Reale SC, 2021, PAEDIATR PERINAT EP, V35, P24, DOI 10.1111/ppe.12743
  41. Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101613
  42. SIEGEL S, 1988, NONPARAMETRIC STAT B
  43. Silva-Malta MCF, 2021, TRANSFUSION MED, V31, P206, DOI 10.1111/tme.12733
  44. Sutton D, 2020, NEW ENGL J MED, V382, P2163, DOI 10.1056/NEJMc2009316
  45. Vandenbroucke JP, 2007, PLOS MED, V4, P1628, DOI 10.1371/journal.pmed.0040297
  46. Wastnedge EAN, 2021, PHYSIOL REV, V101, P303, DOI 10.1152/physrev.00024.2020
  47. Wolff D, 2021, INFECTION, V49, P15, DOI 10.1007/s15010-020-01509-1
  48. Zambrano LD, 2020, MMWR-MORBID MORTAL W, V69, P1641, DOI 10.15585/mmwr.mm6944e3
  49. Zhang J, 2020, CLIN MICROBIOL INFEC, V26, P767, DOI 10.1016/j.cmi.2020.04.012
  50. Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3

Coleções
Artigos e Materiais de Revistas Científicas - FM/MOG
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/46
Artigos e Materiais de Revistas Científicas - LIM/57
Carregar mais